Viruses - seeking and destroying the tumor program
- PMID: 16299526
- DOI: 10.1038/sj.onc.1209047
Viruses - seeking and destroying the tumor program
Abstract
DNA viruses have enormous utility in cancer research, both as tools for tumor target discovery as well as agents for lytic cancer therapies. This is because there is a profound functional overlap between the DNA viral and tumor cell programs. DNA viruses encode proteins that elicit growth deregulation in infected cells similar to that engendered by mutations in tumor cells. Evolution has refined viral proteins to target the critical cellular hubs that regulate growth. Thus, viral proteins are discriminating biochemical probes that can be used to identify and characterize novel tumor targets. Moreover, the overlap between the DNA viral and tumor programs can also be exploited for the development of lytic cancer therapies. Discovering whether tumor cells selectively complement the replication of viral mutants can reveal novel oncolytic viral therapies, as well as unexpected tumor properties. For example, altered RNA export was recently uncovered as a novel tumor cell property that underlies ONYX-015 replication, a promising oncolytic adenoviral therapy. A perspective is provided on how adenovirus could be systematically exploited to map the requisite role, or indeed the redundancy, of cellular pathways that act in an integrated program to elicit pathological replication. This knowledge has important applications for the rational design of the next generation of oncolytic viruses, as well as the discovery of efficacious combination cancer therapies.
Similar articles
-
Viruses: tools for tumor target discovery, and agents for oncolytic therapies - an introduction.Oncogene. 2005 Nov 21;24(52):7636-9. doi: 10.1038/sj.onc.1209035. Oncogene. 2005. PMID: 16299525 No abstract available.
-
Future prospects for oncolytic therapy.Oncogene. 2005 Nov 21;24(52):7817-9. doi: 10.1038/sj.onc.1209064. Oncogene. 2005. PMID: 16299540
-
Oncolytic adenoviruses - selective retargeting to tumor cells.Oncogene. 2005 Nov 21;24(52):7775-91. doi: 10.1038/sj.onc.1209044. Oncogene. 2005. PMID: 16299537 Review.
-
To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control.Oncogene. 2005 Nov 21;24(52):7697-709. doi: 10.1038/sj.onc.1209053. Oncogene. 2005. PMID: 16299530 Review.
-
Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.Semin Oncol. 2005 Dec;32(6):537-48. doi: 10.1053/j.seminoncol.2005.09.007. Semin Oncol. 2005. PMID: 16338419 Review.
Cited by
-
Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.Cancer Gene Ther. 2010 Apr;17(4):244-55. doi: 10.1038/cgt.2009.70. Epub 2009 Oct 2. Cancer Gene Ther. 2010. PMID: 19798121 Free PMC article.
-
Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase.Mol Ther Oncolytics. 2017 Sep 8;7:37-44. doi: 10.1016/j.omto.2017.09.002. eCollection 2017 Dec 15. Mol Ther Oncolytics. 2017. PMID: 29034314 Free PMC article.
-
Increasing the efficacy of oncolytic adenovirus vectors.Viruses. 2010 Sep;2(9):1844-1866. doi: 10.3390/v2091844. Epub 2010 Aug 27. Viruses. 2010. PMID: 21994711 Free PMC article.
-
Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer.J Cell Mol Med. 2020 Sep;24(18):10744-10755. doi: 10.1111/jcmm.15697. Epub 2020 Jul 29. J Cell Mol Med. 2020. PMID: 32725966 Free PMC article.
-
Viral hijacking of cellular metabolism.BMC Biol. 2019 Jul 18;17(1):59. doi: 10.1186/s12915-019-0678-9. BMC Biol. 2019. PMID: 31319842 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
